TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Newly diagnosed symptomatic multiple myeloma confirmed by the following:~  * Bone marrow plasmacytosis with at least 10% plasma cells or sheets of plasma cells or biopsy-proven plasmacytosis~ * Monoclonal protein (M protein) at least 1.0 g/dL on serum protein electrophoresis or at least 200 mg of monoclonal light chain on a 24-hour urine protein electrophoresis~* No smoldering myeloma or monoclonal gammopathy of undetermined significance~PATIENT CHARACTERISTICS:~Age:~* 18 and over~Performance status:~* ECOG 0-2~Life expectancy:~* Not specified~Hematopoietic:~* Absolute neutrophil count greater than 1,000/mm\^3~* Platelet count greater than 50,000/mm\^3~* Hemoglobin greater than 7 g/dL~Hepatic:~* Bilirubin no greater than 1.5 mg/dL~* ALT and AST no greater than 2.5 times upper limit of normal~Renal:~* Creatinine less than 3 mg/dL~Cardiovascular:~* No prior or concurrent deep venous thrombosis~Other:~* Prior malignancy allowed provided the following criteria are met:~  * Received prior treatment with curative intent~ * Free of disease for the time period appropriate for cure of the specific cancer~* No grade 2 or greater peripheral neuropathy due to other medical conditions~* No active infection~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use 1 highly effective method and 1 additional method of contraception for 1 month before, during, and for 4 weeks after study for women and effective barrier contraception for men during and for 4 weeks after study participation~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* No prior biologic therapy for multiple myeloma~* No other concurrent biologic therapy for multiple myeloma~Chemotherapy:~* No prior chemotherapy for multiple myeloma~* No other concurrent chemotherapy for multiple myeloma~Endocrine therapy:~* More than 6 months since prior systemic dexamethasone or glucocorticoids~* No concurrent corticosteroids~Radiotherapy:~* At least 4 weeks since prior palliative, localized radiotherapy~* Concurrent palliative, localized radiotherapy allowed at the physician's discretion~Surgery:~* Not specified~Other:~* No prior systemic therapy for multiple myeloma, except bisphosphonates~* No concurrent anticoagulant therapy for deep vein thrombosis~* No concurrent barbiturates or alcohol (thalidomide arm)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Third Dose of Moderna COVID-19 Vaccine in Transplant Recipients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Solid organ transplant recipient who has previously received Moderna vaccine at 0 and 1 months~* Able to provide informed consent~Exclusion Criteria:~* Anaphylaxis or allergic reaction to Moderna vaccine

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental group (Type: ACTIVE_COMPARATOR): Participants will receive a one dose of mRNA-1273 vaccine 0.5mL i.m. in deltoid muscle
- Comparator Group (Type: PLACEBO_COMPARATOR): Participants will receive one dose of normal saline injection 0.5mL i.m. in deltoid muscle

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Nivolumab (BMS-936558) vs. Everolimus in Pre-Treated Advanced or Metastatic Clear-cell Renal Cell Carcinoma (CheckMate 025)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Men \& women ≥18 years of age~* Histologic confirmation of renal cell carcinoma (RCC) with clear-cell component~* Advanced/metastatic RCC~* Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria~* Received 1 or 2 prior anti-angiogenic therapy regimens in advanced or metastatic setting~* No more than 3 total prior systemic treatment regimens in the advanced or metastatic setting, and evidence of progression on or after last treatment regimen received and within 6 months of enrollment~* Karnofsky Performance Score ≥70%~Exclusion Criteria:~* Any Central Nervous System (CNS) metastases or history of CNS metastases~* Prior therapy with an Mammalian target of rapamycin (mTOR) inhibitor~* Any active known or suspected autoimmune disease~* Uncontrolled adrenal insufficiency~* Active chronic liver disease~* Prior malignancy active within past 3 years, except for locally curable cancers~Other protocol-defined inclusion/exclusion criteria apply

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1: Nivolumab (Type: EXPERIMENTAL): Nivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
- Arm 2: Everolimus (Type: ACTIVE_COMPARATOR): Everolimus 10 mg tablets by mouth daily until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Glycaemic Control and Other Clinical Parameters in Adult Type 2 Diabetes Patients on Basal Insulin Initiating Treatment With IDegLira in Routine Clinical Practice in Colombia

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria:~1. Male or female, age above or equal to 18 years at the time of data collection.~2. Patient diagnosed with T2D greater than or equal to 12 months prior to data collection.~3. The decision to initiate treatment with commercially available IDegLira has been made by the patient and the treating physician before, which is independent from the decision to participate in this study.~4. Treated with basal insulin plus/minus OADs prior to initiating IDegLira.~5. Available and documented HbA1c measurement below or equal to 12 weeks prior to IDegLira initiation.~Exclusion criteria:~1. Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation.~2. Diagnosed with type 1 diabetes mellitus, maturity-onset diabetes of the young, latent autoimmune diabetes in adults, gestational diabetes or any hyperglycaemic state other than T2D.~3. Women known to be pregnant or breastfeeding during the conduct of the study.~4. Patients with basal-bolus insulin prior to IDegLira initiation.~5. Participation in another T2D clinical study that involves any clinical intervention or administration of an investigational drug within 3 months prior to initiating IDegLira.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegLira (Type: None): Adult patients with T2D who have initiated treatment with IDegLira a minimum of 26 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Proof-of-concept RCT of Version 3.0 of the Smoking Cessation Smartphone App Smiling Instead of Smoking (SiS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 18+ years of age~* smartphone ownership (Android or iPhone only)~* current nondaily smoker, who smokes at least weekly, and no more than 25 out of the past 30 days~* lifetime history of having smoked 100+ cigarettes~* willing to make a smoking quit attempt~* currently residing in the United States of America~Exclusion Criteria:~* Under 18 years of age~* Does not own an Android or iPhone~* Is not a nondaily smoker, who smokes at least weekly, and no more than 25 out of the past 30 days~* Does not have a lifetime history of having smoked 100+ cigarettes~* Is not willing to make a smoking quit attempt~* Is not currently residing in the United States of America

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Smiling Instead of Smoking (SiS) app (Type: EXPERIMENTAL): Participants will be onboarded (remotely) to the smartphone app Smiling instead of Smoking (SiS), and will be asked to use it for 7 weeks while they quit smoking.
- QuitGuide (QG) app (Type: ACTIVE_COMPARATOR): Participants will be onboarded (remotely) to the smartphone app QuitGuide (QG), and will be asked to use it for 7 weeks while they quit smoking.
- Clearing the Air (CTA) brochure (Type: OTHER): Participants will be onboarded (remotely) to the NCI brochure Clearing the Air (CTA), and will be asked to use it for 7 weeks while they quit smoking.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Relationship Between Vedolizumab Therapeutic Drug Monitoring, Biomarkers of Inflammation and Clinical Outcomes

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. The participant or, when applicable, the participant's legally acceptable representative signed and dated a written, informed consent form, which specified secondary use of their data, and any required privacy authorization as part of their enrollment in Takeda Canada's PSP.~2. Received or receiving vedolizumab between the years 2015 and 2020.~Exclusion Criteria:~No exclusion criteria will be applied.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TDM Cohort (Type: None): Participants diagnosed with inflammatory bowel disease (IBD) (UC or CD) within Takeda Canada Patient Support Program (PSP) group who received treatment with vedolizumab 300 milligram (mg), infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 along with the biomarker testing and TDM at pre-specified intervals during their treatment were observed retrospectively.
- Historical Cohort (Type: None): Participants diagnosed with IBD (UC or CD) within Takeda Canada PSP group who received treatment with vedolizumab 300 mg, infusion, intravenously, at Weeks 0, 2, and 6, and every 8 weeks thereafter as per product Health Canada Product Monograph, or every 4 or 6 weeks thereafter as per standard clinical practice between the year 2015 to 2020 but did not undergo biomarker testing or TDM during their treatment were observed retrospectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Open-Label Comparison of Duloxetine to Other Alternatives for the Management of Diabetic Peripheral Neuropathic Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* You must have been diagnosed with Diabetic Neuropathic Pain~* Patient has an average daily pain score greater than or equal to 4 on an 11-point Likert scale, and patient or provider feel that a change from the current gabapentin therapy for pain management is warranted~* Patient is currently treated with gabapentin greater than or equal to 900 milligram/day, has been prescribed the current dose for at least 4 weeks, and has been at least 80% compliant with dosing, according to patient report~* Patient must agree not to change dose of gabapentin between Visits 1 and 2~* You must have stable glycemic control~Exclusion Criteria:~* Are judged prior to randomization to be at suicidal risk as defined by a score of 2 or greater on question 9 of the Beck Depression Inventory-II (BDI-II)~* Current diagnosis or history of hemangiosarcoma~* Patients with New York Heart Association Class III or IV symptoms of congestive heart failure~* Patients with uncontrolled narrow-angle glaucoma~* Presence of a current seizure disorder

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pregabalin (Type: ACTIVE_COMPARATOR): Pregabalin (PGB) 50 milligram (mg) three times a day (TID) (US \& Germany) or 75 mg twice daily (BID) (Canada), orally (PO) for 2 weeks, then PGB 100 mg TID (US \& Germany) or 150 mg BID (Canada), PO for 10 weeks.
- Duloxetine (Type: EXPERIMENTAL): Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then DLX 60 mg QD, PO for 11 weeks.
- Gabapentin + Duloxetine (Type: EXPERIMENTAL): Stable Gabapentin (GAB) + Duloxetine (DLX) 30 milligram (mg) once daily (QD), orally (PO) for 1 week, then stable GAB + DLX 60 mg QD, PO for 11 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Preservative-free Tafluprost/Timolol Fixed Combination: Morning vs Evening Dosing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. age between 21-85 years;~2. mild to moderate glaucomatous disc damage and visual field loss (less than -12 dB mean deviation visual field loss attributed to glaucoma and 0.8 or better vertical cup-to-disc ratio);~3. visual acuity greater than 0.1 in the study eye;~4. open anterior chamber angles;~5. in each patient the diagnosis of open-angle glaucoma will be made by the principal investigator based on the European Glaucoma Society criteria;~6. study patients will have to demonstrate a reliable visual field (at least two visual fields with less than 20% fixation losses, false positives, or negatives);~7. patient should understand the study instructions and to be willing to attend all follow-up appointments and should be willing to comply with study medication usage.~Exclusion Criteria:~1. previous history of less than 10% IOP decrease on any IOP-lowering medication;~2. evidence of concurrent conjunctivitis, keratitis, or uveitis in either eye;~3. history of inadequate adherence; intolerance, or contraindication to either prostaglandins, β-blockers, dorzolamide, or benzalconium chloride (BAK);~4. severe ocular surface disease, intraocular conventional or laser surgery in the study eye (within 6 months prior to enrolment);~5. previous history of ocular trauma;~6. use of corticosteroids (within 3 months before the enrolment) and use of contact lenses;~7. patients will also be excluded if on baseline exam they show clinical evidence of inflammation, signs of ocular infection (except blepharitis), signs of any corneal abnormality that will affect subsequent IOP measurements;~8. unwillingness to participate in the trial;~9. females of childbearing potential or lactating mothers.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Tafluprost/timolol with PM dosing (Type: ACTIVE_COMPARATOR): Therapy with Tafluprost/timolol fixed combination drops dosed PM (20:00)
- Tafluprost/timolol with AM dosing (Type: ACTIVE_COMPARATOR): Therapy with Tafluprost/timolol fixed combination drops dosed AM (08:00)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ACVBP Plus Rituximab in Patients Aged From 18 to 59 Years With High-risk Diffuse Large B-cell Lymphoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~Patient with histologically proven CD20+ diffuse large B-cell lymphoma (WHO classification).~Age from 18 to 59 years, eligible for transplant. Patient not previously treated. Age adjusted IPI = 2 or 3 With a minimum life expectancy of 3 months Negative HIV, HBV and HCV serologies \< 4 weeks (except after vaccination). Having signed a written informed consent.~Exclusion Criteria:~Any history of treated or non-treated indolent lymphoma. However, patients not previously diagnosed and having a diffuse large B-cell lymphoma with some small cell infiltration in bone marrow or lymph node may be included.~Central nervous system or meningeal involvement by lymphoma. Contra-indication to any drug contained in the chemotherapy regimens. Poor renal function (creatinin level \>150 mmol/l), poor hepatic function (total bilirubin level \>30 mmol/l, transaminases \>2.5 maximum normal level) unless these abnormalities are related to the lymphoma.~Poor bone marrow reserve as defined by neutrophils \<1.5 G/l or platelets \<100 G/l, unless related to bone marrow infiltration.~Any history of cancer during the last 5 years with the exception of non-melanoma skin tumors or stage 0 (in situ) cervical carcinoma.~Any serious active disease (according to the investigator's decision). Treatment with any investigational drug within 30 days before planned first cycle of chemotherapy and during the study.~Pregnant or lactating women Adult patient under tutelage.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 59 Years
- Healthy Volunteers: f

Study Arms:
- R-AC (Type: EXPERIMENTAL): rituximab + doxorubicin + cyclophosphamide + autologous stem cell transplantation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Epidermal Grafting in Wound Healing

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Male or female~2. Age 18-90~3. Wound measuring more than 1cm x 1cm and lesser than 5cm x 5cm (1% TBSA)~4. Wound with clean, healthy granulating bed, with minimal adherent slough~5. Patient understands and is willing to participate and can comply with weekly visits and follow-up regime~Exclusion Criteria:~1. Wound with active infection~2. Wound at plantar of the foot~3. Patients unsuitable for Split Skin Grafting~4. Previous history of excessive bleeding associated with surgical biopsies or trauma~5. Allergies to tegaderm (and other dressings used in the study)~6. Known uncontrolled Diabetes Mellitus, as measured by an HbA1c \> 10%.~7. Presence of one or more medical conditions, including renal, hepatic, hematologic, active auto-immune or immune diseases that, would make the subject an inappropriate candidate for this ulcer healing study~8. Patient not fit for surgery (ASA classification \> 4)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: t

Study Arms:
- Epidermal Graft (Type: EXPERIMENTAL): The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts as per existing normal clinical practice.
- Split Thickness Skin Graft (Type: EXPERIMENTAL): Split thickness skin graft will be harvested using air dermatome as per normal clinical practise.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Healthy Adults

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* individuals who are 19-65 years of age inclusive and who, after the nature of the study has been explained have provided written informed consent~* individuals who are available for all visits and telephone calls scheduled for the study;~* individuals who are in good health~Exclusion Criteria:~* individuals with a previous or suspected disease caused by N. meningitidis~* individuals with previous immunization with a meningococcal vaccine or vaccine containing meningococcal antigen(s)~* individuals with previous or suspected disease caused by N. meningitidis~* individuals with any serious acute, chronic or progressive disease~* individuals who are pregnant or breastfeeding

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 65 Years
- Healthy Volunteers: t

Study Arms:
- Novartis MenACWY Vaccine (19 to 55 Years) (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate vaccine administered to subjects 19 years to 55 years
- Licensed polysaccharide vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide vaccine
- Licensed Conjugate Vaccine (Type: ACTIVE_COMPARATOR): Licensed meningococcal ACWY polysaccharide-protein conjugate vaccine
- Novartis MenACWY Vaccine (56 to 65 Years) (Type: EXPERIMENTAL): Novartis meningococcal ACWY conjugate vaccine administered to subjects 56 years to 65 years

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete